{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:48:09Z","timestamp":1791996489690,"version":"4.4.0"},"reference-count":143,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":267,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The high disease burden and bidirectional relationship of chronic kidney disease (CKD), heart failure (HF) and other cardiovascular disease (CVD) necessitate the need for early diagnosis of these diseases. While current screening and detection methods are recommended by CKD and CVD guidelines, their adoption in practice is low. Urine albumin-to-creatinine ratio (uACR) is recognized as a diagnostic marker for CKD and a prognostic marker for CKD progression, HF and CVD outcomes, therefore albuminuria changes have been accepted as a surrogate outcome for kidney and cardiovascular endpoints. Furthermore, clinical trials investigating guideline-directed medical therapies have shown that uACR reductions are accompanied by risk reductions for cardiovascular, HF and other CKD outcomes. However, uACR is not routinely measured in patients at risk of kidney and heart disease, and its utility for detection, risk stratification and prediction models may not be fully appreciated in routine clinical practice. This review will discuss the effectiveness and implications of uACR screening as a method for heart and kidney disease diagnosis and risk assessment.<\/jats:p>","DOI":"10.1002\/ejhf.3683","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T22:35:57Z","timestamp":1748385357000},"page":"2357-2371","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Albuminuria as a Diagnostic Criterion and a Therapeutic Target in Heart Failure and Other Cardiovascular Disease"],"prefix":"10.1093","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6362-0253","authenticated-orcid":false,"given":"Biykem","family":"Bozkurt","sequence":"first","affiliation":[{"name":"Department of Medicine, Cardiology Section, Winters Center for Heart Failure Research, Cardiovascular Research Institute, Baylor College of Medicine , Houston, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Rossignol","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lorraine, Centre d'Investigations Cliniques-Plurith\u00e9matique 1433 CHRU de Nancy, U1116 Inserm and F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists) , Nancy ,","place":["France"]},{"name":"Medicine and Nephrology-Dialysis Departments, Princess Grace Hospital , Monaco ,","place":["Monaco"]},{"name":"Monaco Private Hemodialysis Centre , Monaco ,","place":["Monaco"]},{"name":"M-CRIN (Monaco Clinical Research Infrastructure Network) , Monaco ,","place":["Monaco"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A.","family":"Vassalotti","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai , New York, NY ,","place":["USA"]},{"name":"National Kidney Foundation, Inc , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,27]]},"reference":[{"key":"2026021721502565300_ejhf3683-bib-0001","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1161\/CIR.0000000000001186","article-title":"A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: A scientific statement from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"2026021721502565300_ejhf3683-bib-0002","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41581-023-00789-8","article-title":"Chronic cardiovascular-kidney disorder: A new conceptual framework","volume":"20","author":"Zoccali","year":"2024","journal-title":"Nat Rev Nephrol"},{"key":"2026021721502565300_ejhf3683-bib-0003","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","journal-title":"Kidney Int"},{"key":"2026021721502565300_ejhf3683-bib-0004","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/S0140-6736(12)61350-6","article-title":"Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: A meta-analysis","volume":"380","author":"Fox","year":"2012","journal-title":"Lancet"},{"key":"2026021721502565300_ejhf3683-bib-0005","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.kint.2019.07.012","article-title":"A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases","volume":"96","author":"Jager","year":"2019","journal-title":"Kidney Int"},{"key":"2026021721502565300_ejhf3683-bib-0006","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1093\/eurheartj\/ehw334","article-title":"Cardiovascular disease in Europe: epidemiological update 2016","volume":"37","author":"Townsend","year":"2016","journal-title":"Eur Heart J"},{"key":"2026021721502565300_ejhf3683-bib-0007","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1016\/j.jacc.2017.08.074","article-title":"Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes","volume":"70","author":"Shah","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026021721502565300_ejhf3683-bib-0008","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med"},{"key":"2026021721502565300_ejhf3683-bib-0009","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jacc.2023.04.052","article-title":"Cardiovascular outcomes in patients with diabetes and kidney disease: JACC review topic of the week","volume":"82","author":"Morales","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026021721502565300_ejhf3683-bib-0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2023.100604","article-title":"CKD progression risk and subsequent cause of death: A population-based cohort study","volume":"5","author":"Rai","year":"2023","journal-title":"Kidney Med"},{"key":"2026021721502565300_ejhf3683-bib-0011","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/j.jacc.2022.11.001","article-title":"Global Burden of Cardiovascular Diseases and Risks Collaboration, 1990-2021","volume":"80","author":"Lindstrom","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026021721502565300_ejhf3683-bib-0012","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/eurjpc\/zwaa147","article-title":"Burden of heart failure and underlying causes in 195 countries and territories from 1990 to 2017","volume":"28","author":"Bragazzi","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"2026021721502565300_ejhf3683-bib-0013","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1161\/01.CIR.0000095676.90936.80","article-title":"Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention","volume":"108","author":"Sarnak","year":"2003","journal-title":"Circulation"},{"key":"2026021721502565300_ejhf3683-bib-0014","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1159\/000368915","article-title":"Association between chronic kidney disease progression and cardiovascular disease: Results from the CRIC study","volume":"40","author":"Rahman","year":"2014","journal-title":"Am J Nephrol"},{"key":"2026021721502565300_ejhf3683-bib-0015","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/j.jacc.2022.11.005","article-title":"The Global Burden of Cardiovascular Diseases and Risk","volume":"80","author":"Vaduganathan","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026021721502565300_ejhf3683-bib-0016","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1161\/CIRCRESAHA.122.321748","article-title":"The cardio-kidney patient: Epidemiology, clinical characteristics and therapy","volume":"132","author":"Schuett","year":"2023","journal-title":"Circ Res"},{"key":"2026021721502565300_ejhf3683-bib-0017","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1097\/01.ASN.0000129982.10611.4C","article-title":"Medicare patients with cardiovascular disease have a high prevalence of chronic kidney disease and a high rate of progression to end-stage renal disease","volume":"15","author":"McClellan","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"2026021721502565300_ejhf3683-bib-0018","article-title":"Diagnostic value and utility of commonly used biomarkers of cardiac and renal function in cardiorenal syndromes: A narrative review","volume":"33","author":"Delali\u0107","year":"2023","journal-title":"Biochem Med (Zagreb)"},{"key":"2026021721502565300_ejhf3683-bib-0019","volume-title":"Chronic kidney disease: assessment and management","author":"National Institute for Health and Care Excellence"},{"key":"2026021721502565300_ejhf3683-bib-0020","first-page":"154","article-title":"Serum creatinine and occurrence and severity of coronary artery disease","volume":"73","author":"Bagheri","year":"2019","journal-title":"Mediev Archaeol"},{"key":"2026021721502565300_ejhf3683-bib-0021","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.34067\/KID.0003202022","article-title":"Advantages, limitations, and clinical considerations in using cystatin C to estimate GFR","volume":"3","author":"Chen","year":"2022","journal-title":"Kidney360"},{"key":"2026021721502565300_ejhf3683-bib-0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2023.100628","article-title":"Estimated GFR accuracy when cystatin C- and creatinine-based estimates are discrepant in older adults","volume":"5","author":"Potok","year":"2023","journal-title":"Kidney Med"},{"key":"2026021721502565300_ejhf3683-bib-0023","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S2213-8587(18)30313-9","article-title":"Change in albuminuria and subsequent risk of end-stage kidney disease: An individual participant-level consortium meta-analysis of observational studies","volume":"7","author":"Coresh","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026021721502565300_ejhf3683-bib-0024","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2019.06.009","article-title":"Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: A scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency","volume":"75","author":"Levey","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"2026021721502565300_ejhf3683-bib-0025","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes","volume":"44","author":"Marx","year":"2023","journal-title":"Eur Heart J"},{"key":"2026021721502565300_ejhf3683-bib-0026","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1681\/ASN.2010091001","article-title":"Changes in albuminuria predict mortality and morbidity in patients with vascular disease","volume":"22","author":"Schmieder","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"2026021721502565300_ejhf3683-bib-0027","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1093\/aje\/kwh037","article-title":"A prospective study of microalbuminuria and incident coronary heart disease and its prognostic significance in a British population: the EPIC-Norfolk study","volume":"159","author":"Yuyun","year":"2004","journal-title":"Am J Epidemiol"},{"key":"2026021721502565300_ejhf3683-bib-0028","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/S0272-6386(03)00742-X","article-title":"Microalbuminuria and all-cause mortality in 2,089 apparently healthy individuals: A 4.4-year follow-up study. The Nord-Tr\u00f8ndelag Health Study (HUNT), Norway","volume":"42","author":"Romundstad","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"2026021721502565300_ejhf3683-bib-0029","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jama.286.4.421","article-title":"Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals","volume":"286","author":"Gerstein","year":"2001","journal-title":"JAMA"},{"key":"2026021721502565300_ejhf3683-bib-0030","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.atherosclerosis.2007.07.029","article-title":"Cardiovascular and mortality risk prediction and stratification using urinary albumin excretion in older adults ages 68-102: The Cardiovascular Health Study","volume":"197","author":"Cao","year":"2008","journal-title":"Atherosclerosis"},{"key":"2026021721502565300_ejhf3683-bib-0031","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1161\/01.CIR.0000031732.78052.81","article-title":"Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population","volume":"106","author":"Hillege","year":"2002","journal-title":"Circulation"},{"key":"2026021721502565300_ejhf3683-bib-0032","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.amjcard.2007.12.030","article-title":"Usefulness of microalbuminuria versus the metabolic syndrome as a predictor of cardiovascular disease in women and men &gt;40\u2009years of age (from the Rancho Bernardo Study)","volume":"101","author":"Jassal","year":"2008","journal-title":"Am J Cardiol"},{"key":"2026021721502565300_ejhf3683-bib-0033","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1111\/j.1523-1755.2005.00526.x","article-title":"Albuminuria and incident coronary heart disease in Australian aboriginal people","volume":"68","author":"Wang","year":"2005","journal-title":"Kidney Int"},{"key":"2026021721502565300_ejhf3683-bib-0034","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1681\/ASN.V133745","article-title":"Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States","volume":"13","author":"Muntner","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"2026021721502565300_ejhf3683-bib-0035","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"2026021721502565300_ejhf3683-bib-0036","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"2026021721502565300_ejhf3683-bib-0037","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S2213-8587(15)00040-6","article-title":"Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: A collaborative meta-analysis of individual participant data","volume":"3","author":"Matsushita","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026021721502565300_ejhf3683-bib-0038","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"2026021721502565300_ejhf3683-bib-0039","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1161\/01.CIR.0000139860.33974.28","article-title":"Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy","volume":"110","author":"Zeeuw","year":"2004","journal-title":"Circulation"},{"key":"2026021721502565300_ejhf3683-bib-0040","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1097\/HJH.0b013e32835200f9","article-title":"An initial reduction in serum uric acid during angiotensin receptor blocker treatment is associated with cardiovascular protection: A post-hoc analysis of the RENAAL and IDNT trials","volume":"30","author":"Smink","year":"2012","journal-title":"J Hypertens"},{"key":"2026021721502565300_ejhf3683-bib-0041","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"2026021721502565300_ejhf3683-bib-0042","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"key":"2026021721502565300_ejhf3683-bib-0043","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-8587(23)00322-4","article-title":"Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: Secondary analyses of the EMPA-KIDNEY trial","volume":"12","author":"EMPA-KIDNEY Collaborative Group","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026021721502565300_ejhf3683-bib-0044","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"2026021721502565300_ejhf3683-bib-0045","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"2026021721502565300_ejhf3683-bib-0046","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2026021721502565300_ejhf3683-bib-0047","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1161\/CIRCULATIONAHA.122.059785","article-title":"Empagliflozin for heart failure with preserved left ventricular ejection fraction with and without diabetes","volume":"146","author":"Filippatos","year":"2022","journal-title":"Circulation"},{"key":"2026021721502565300_ejhf3683-bib-0048","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"2026021721502565300_ejhf3683-bib-0049","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1161\/CIRCULATIONAHA.120.051685","article-title":"Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: Insights from EMPEROR-Reduced","volume":"143","author":"Zannad","year":"2021","journal-title":"Circulation"},{"key":"2026021721502565300_ejhf3683-bib-0050","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1001\/jamacardio.2023.4664","article-title":"Decline in estimated glomerular filtration rate after dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: A prespecified secondary analysis of the DELIVER randomized cinical trial","volume":"9","author":"Mc Causland","year":"2024","journal-title":"JAMA Cardiol"},{"key":"2026021721502565300_ejhf3683-bib-0051","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"2026021721502565300_ejhf3683-bib-0052","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1161\/CIRCULATIONAHA.120.051675","article-title":"Effect of dapagliflozin on clinical outcomes in patients with chronic kidney disease, with and without cardiovascular disease","volume":"143","author":"McMurray","year":"2021","journal-title":"Circulation"},{"key":"2026021721502565300_ejhf3683-bib-0053","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"2026021721502565300_ejhf3683-bib-0054","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.016976","article-title":"Short-term changes in albuminuria and risk of cardiovascular and renal outcomes in type 2 diabetes mellitus: A post hoc analysis of the EMPA-REG OUTCOME trial","volume":"9","author":"Waijer","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2026021721502565300_ejhf3683-bib-0055","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"2026021721502565300_ejhf3683-bib-0056","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"2026021721502565300_ejhf3683-bib-0057","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-8587(18)30141-4","article-title":"Canagliflozin and renal outcomes in type 2 diabetes: Results from the CANVAS Program randomised clinical trials","volume":"6","author":"Perkovic","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026021721502565300_ejhf3683-bib-0058","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N Engl J Med"},{"key":"2026021721502565300_ejhf3683-bib-0059","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1007\/s00125-021-05407-5","article-title":"Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: An analysis from the randomised VERTIS CV trial","volume":"64","author":"Cherney","year":"2021","journal-title":"Diabetologia"},{"key":"2026021721502565300_ejhf3683-bib-0060","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"2026021721502565300_ejhf3683-bib-0061","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"2026021721502565300_ejhf3683-bib-0062","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.118.005288","article-title":"Prognostic value of albuminuria and influence of spironolactone in heart failure with preserved ejection fraction","volume":"11","author":"Selvaraj","year":"2018","journal-title":"Circ Heart Fail"},{"key":"2026021721502565300_ejhf3683-bib-0063","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"2026021721502565300_ejhf3683-bib-0064","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(19)32135-X","article-title":"Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): A phase 2, randomised, double-blind, placebo-controlled trial","volume":"394","author":"Agarwal","year":"2019","journal-title":"Lancet"},{"key":"2026021721502565300_ejhf3683-bib-0065","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/ckj\/sfac234","article-title":"A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease","volume":"16","author":"Agarwal","year":"2023","journal-title":"Clin Kidney J"},{"key":"2026021721502565300_ejhf3683-bib-0066","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jchf.2018.02.004","article-title":"Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure","volume":"6","author":"Damman","year":"2018","journal-title":"JACC Heart Fail"},{"key":"2026021721502565300_ejhf3683-bib-0067","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2026021721502565300_ejhf3683-bib-0068","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"2026021721502565300_ejhf3683-bib-0069","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"45","author":"Davies","year":"2022","journal-title":"Diabetes Care"},{"key":"2026021721502565300_ejhf3683-bib-0070","doi-asserted-by":"crossref","first-page":"S239","DOI":"10.2337\/dc25-S011","article-title":"11. Chronic kidney disease and risk management: Standards of care in diabetes-2025","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","journal-title":"Diabetes Care"},{"key":"2026021721502565300_ejhf3683-bib-0071","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/ejhf.3024","article-title":"2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"26","author":"McDonagh","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026021721502565300_ejhf3683-bib-0072","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"key":"2026021721502565300_ejhf3683-bib-0073","doi-asserted-by":"crossref","first-page":"S207","DOI":"10.2337\/dc25-S010","article-title":"10. Cardiovascular disease and risk management: Standards of care in diabetes-2025","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","journal-title":"Diabetes Care"},{"key":"2026021721502565300_ejhf3683-bib-0074","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: Collaborative meta-analysis of large placebo-controlled trials","volume":"400","author":"Nuffield Department of Population Health Renal Studies Group","year":"2022","journal-title":"Lancet"},{"key":"2026021721502565300_ejhf3683-bib-0075","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026021721502565300_ejhf3683-bib-0076","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s13300-023-01391-8","article-title":"Comparative efficacy of novel antidiabetic drugs on albuminuria outcomes in type 2 diabetes: A systematic review","volume":"14","author":"Liu","year":"2023","journal-title":"Diabetes Ther"},{"key":"2026021721502565300_ejhf3683-bib-0077","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1161\/CIRCULATIONAHA.118.034818","article-title":"Effects of sacubitril\/valsartan versus irbesartan in patients with chronic kidney disease","volume":"138","author":"Haynes","year":"2018","journal-title":"Circulation"},{"key":"2026021721502565300_ejhf3683-bib-0078","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2023.108418","article-title":"Unmet needs and opportunities for optimal management of patients with type 2 diabetes and chronic kidney disease","volume":"37","author":"Pantalone","year":"2023","journal-title":"J Diabetes Complications"},{"key":"2026021721502565300_ejhf3683-bib-0079","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.kint.2020.10.012","article-title":"The case for early identification and intervention of chronic kidney disease: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"99","author":"Shlipak","year":"2021","journal-title":"Kidney Int"},{"key":"2026021721502565300_ejhf3683-bib-0080","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1001\/jama.2015.0602","article-title":"Glomerular filtration rate and albuminuria for detection and staging of acute and chronic kidney disease in adults: A systematic review","volume":"313","author":"Levey","year":"2015","journal-title":"JAMA"},{"key":"2026021721502565300_ejhf3683-bib-0081","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/j.ekir.2022.05.033","article-title":"Low adherence to Kidney Disease: Improving Global Outcomes 2012 CKD clinical practice guidelines despite clear evidence of utility","volume":"7","author":"James","year":"2022","journal-title":"Kidney Int Rep"},{"key":"2026021721502565300_ejhf3683-bib-0082","doi-asserted-by":"crossref","DOI":"10.1177\/21501327211003683","article-title":"Optimal early diagnosis and monitoring of diabetic kidney disease in type 2 diabetes mellitus: Addressing the barriers to albuminuria testing","volume":"12","author":"Christofides","year":"2021","journal-title":"J Prim Care Community Health"},{"key":"2026021721502565300_ejhf3683-bib-0083","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cardfail.2015.10.009","article-title":"Prevalence of albuminuria in a general population cohort of patients with established chronic heart failure","volume":"22","author":"Odutayo","year":"2016","journal-title":"J Card Fail"},{"key":"2026021721502565300_ejhf3683-bib-0084","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1053\/j.ajkd.2011.02.391","article-title":"High-normal albuminuria and risk of heart failure in the community","volume":"58","author":"Blecker","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"2026021721502565300_ejhf3683-bib-0085","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0140-6736(09)61378-7","article-title":"Albuminuria in chronic heart failure: Prevalence and prognostic importance","volume":"374","author":"Jackson","year":"2009","journal-title":"Lancet"},{"key":"2026021721502565300_ejhf3683-bib-0086","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1161\/CIR.0000000000001191","article-title":"Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: A scientific statement from the American Heart Association","volume":"148","author":"Khan","year":"2023","journal-title":"Circulation"},{"key":"2026021721502565300_ejhf3683-bib-0087","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jacc.2022.10.028","article-title":"Albuminuria and heart failure: JACC state-of-the-art review","volume":"81","author":"Khan","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026021721502565300_ejhf3683-bib-0088","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s12882-016-0303-x","article-title":"Microvascular endothelial dysfunction is associated with albuminuria and CKD in older adults","volume":"17","author":"Seliger","year":"2016","journal-title":"BMC Nephrol"},{"key":"2026021721502565300_ejhf3683-bib-0089","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1681\/ASN.2006050517","article-title":"Microalbuminuria as an early marker for cardiovascular disease","volume":"17","author":"Zeeuw","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"2026021721502565300_ejhf3683-bib-0090","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jacc.2008.08.080","article-title":"Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease","volume":"53","author":"Damman","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2026021721502565300_ejhf3683-bib-0091","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.ejheart.2008.07.001","article-title":"Urinary neutrophil gelatinase associated lipocalin (NGAL), a marker of tubular damage, is increased in patients with chronic heart failure","volume":"10","author":"Damman","year":"2008","journal-title":"Eur J Heart Fail"},{"key":"2026021721502565300_ejhf3683-bib-0092","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.kint.2023.10.016","article-title":"Executive summary of the KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease: Known knowns and known unknowns","volume":"105","author":"Levin","year":"2024","journal-title":"Kidney Int"},{"key":"2026021721502565300_ejhf3683-bib-0093","volume-title":"Quick reference guide on kidney disease screening","author":"National Kidney Foundation","year":"2024"},{"key":"2026021721502565300_ejhf3683-bib-0094","volume-title":"Hypertension in pregnancy: Diagnosis and management","author":"National Institute for Health and Care Excellence"},{"key":"2026021721502565300_ejhf3683-bib-0095","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/rheumatology\/kex286","article-title":"The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults","volume":"57","author":"Gordon","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"2026021721502565300_ejhf3683-bib-0096","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1038\/ki.2010.550","article-title":"Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts","volume":"79","author":"Astor","year":"2011","journal-title":"Kidney Int"},{"key":"2026021721502565300_ejhf3683-bib-0097","doi-asserted-by":"crossref","first-page":"7851","DOI":"10.1038\/s41598-021-86541-3","article-title":"The ratio and difference of urine protein-to-creatinine ratio and albumin-to-creatinine ratio facilitate risk prediction of all-cause mortality","volume":"11","author":"Chang","year":"2021","journal-title":"Sci Rep"},{"key":"2026021721502565300_ejhf3683-bib-0098","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1093\/jalm\/jfad022","article-title":"AACC\/NKF guidance document on improving equity in chronic kidney disease care","volume":"8","author":"Pierre","year":"2023","journal-title":"J Appl Lab Med"},{"key":"2026021721502565300_ejhf3683-bib-0099","article-title":"Proteinuria and albuminuria at point of care","volume":"2","author":"Cassia","year":"2016","journal-title":"Nephrol @ Point Care"},{"key":"2026021721502565300_ejhf3683-bib-0100","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1440-1797.2010.01314.x","article-title":"Proteinuria versus albuminuria in chronic kidney disease","volume":"15","author":"Guh","year":"2010","journal-title":"Nephrology (Carlton)"},{"key":"2026021721502565300_ejhf3683-bib-0101","article-title":"Proteinuria detected by urine dipstick test as a risk factor for atrial fibrillation: A nationwide population-based study","volume":"7","author":"Lim","year":"2017","journal-title":"Sci Rep"},{"key":"2026021721502565300_ejhf3683-bib-0102","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2188\/jea.JE20140074","article-title":"Epidemiology of chronic kidney disease, with special emphasis on chronic kidney disease of uncertain etiology, in the north central region of Sri Lanka","volume":"25","author":"Jayasekara","year":"2015","journal-title":"J Epidemiol"},{"key":"2026021721502565300_ejhf3683-bib-0103","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1186\/s12967-021-02934-y","article-title":"Dipstick proteinuria and risk of type 2 diabetes mellitus: A nationwide population-based cohort study","volume":"19","author":"Jeon","year":"2021","journal-title":"J Transl Med"},{"key":"2026021721502565300_ejhf3683-bib-0104","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.26230","article-title":"Estimated prevalence and testing for albuminuria in US adults at risk for chronic kidney disease","volume":"6","author":"Chu","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2026021721502565300_ejhf3683-bib-0105","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.annepidem.2020.12.004","article-title":"Urinary albumin-to-creatinine ratio within normal range and all-cause or cardiovascular mortality among U.S. adults enrolled in the NHANES during 1999-2015","volume":"55","author":"Inoue","year":"2021","journal-title":"Ann Epidemiol"},{"key":"2026021721502565300_ejhf3683-bib-0106","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.2337\/dc20-2715","article-title":"Chronic kidney disease testing among primary care patients with type 2 diabetes across 24 U.S. health care organizations","volume":"44","author":"Stempniewicz","year":"2021","journal-title":"Diabetes Care"},{"key":"2026021721502565300_ejhf3683-bib-0107","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfad137","article-title":"Cost-effectiveness of screening for chronic kidney disease in the general adult population: A systematic review","volume":"17","author":"Yeo","year":"2024","journal-title":"Clin Kidney J"},{"key":"2026021721502565300_ejhf3683-bib-0108","article-title":"Targeted screening in the UK: A narrow concept with broad application","volume":"16","author":"Bobrowska","year":"2022","journal-title":"Lancet Reg Health Eur"},{"key":"2026021721502565300_ejhf3683-bib-0109","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.109043","article-title":"Urine albumin-creatinine ratio is associated with prognosis in patients with diabetic foot osteomyelitis","volume":"180","author":"Yang","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"key":"2026021721502565300_ejhf3683-bib-0110","doi-asserted-by":"crossref","first-page":"S191","DOI":"10.2337\/dc23-S011","article-title":"11. Chronic kidney disease and risk management: Standards of care in diabetes-2023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"key":"2026021721502565300_ejhf3683-bib-0111","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.mayocpiqo.2023.07.002","article-title":"Fulfillment and validity of the kidney health evaluation measure for people with diabetes","volume":"7","author":"Ferr\u00e8","year":"2023","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"key":"2026021721502565300_ejhf3683-bib-0112","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.27396","article-title":"Diagnostic yield of population-based screening for chronic kidney disease in low-income, middle-income, and high-income countries","volume":"4","author":"Tonelli","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2026021721502565300_ejhf3683-bib-0113","doi-asserted-by":"crossref","first-page":"E1076","DOI":"10.1503\/cmaj.201731","article-title":"Impact of point-of-care screening for hypertension, diabetes and progression of chronic kidney disease in rural Manitoba indigenous communities","volume":"193","author":"Harasemiw","year":"2021","journal-title":"CMAJ"},{"key":"2026021721502565300_ejhf3683-bib-0114","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1159\/000455389","article-title":"Insights from screening a racially and ethnically diverse population for chronic kidney disease","volume":"45","author":"Wong","year":"2017","journal-title":"Am J Nephrol"},{"key":"2026021721502565300_ejhf3683-bib-0115","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s10157-011-0551-9","article-title":"Risk factor profiles based on estimated glomerular filtration rate and dipstick proteinuria among participants of the specific health check and guidance system in Japan 2008","volume":"16","author":"Iseki","year":"2012","journal-title":"Clin Exp Nephrol"},{"key":"2026021721502565300_ejhf3683-bib-0116","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s11255-010-9861-1","article-title":"Detection of urinary abnormalities in a community from northern Italy based on the World Kidney Day screening program","volume":"43","author":"Fabbian","year":"2011","journal-title":"Int Urol Nephrol"},{"key":"2026021721502565300_ejhf3683-bib-0117","first-page":"307","article-title":"Screening for asymptomatic kidney disease in high-risk population of Urmia, Iran","volume":"4","author":"Ghafari","year":"2010","journal-title":"Iran J Kidney Dis"},{"key":"2026021721502565300_ejhf3683-bib-0118","doi-asserted-by":"crossref","first-page":"c95","DOI":"10.1159\/000314658","article-title":"The Kidney Evaluation and Awareness Program in Sheffield (KEAPS): A community-based screening for microalbuminuria in a British population","volume":"116","author":"Bello","year":"2010","journal-title":"Nephron Clin Pract"},{"key":"2026021721502565300_ejhf3683-bib-0119","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1053\/j.ajkd.2007.12.011","article-title":"Participant follow-up in the Kidney Early Evaluation Program (KEEP) after initial detection","volume":"51","author":"Collins","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"2026021721502565300_ejhf3683-bib-0120","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1007\/s00125-021-05406-6","article-title":"Screening, prevalence, treatment and control of kidney disease in patients with type 1 and type 2 diabetes in low-to-middle-income countries (2005-2017): the International Diabetes Management Practices Study (IDMPS)","volume":"64","author":"Mbanya","year":"2021","journal-title":"Diabetologia"},{"key":"2026021721502565300_ejhf3683-bib-0121","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/nep.13203","article-title":"Cost-utility analysis of the National Health Screening Program for chronic kidney disease in Korea","volume":"24","author":"Go","year":"2019","journal-title":"Nephrology (Carlton)"},{"key":"2026021721502565300_ejhf3683-bib-0122","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1093\/ndt\/gfn082","article-title":"A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA","volume":"23","author":"Palmer","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"2026021721502565300_ejhf3683-bib-0123","doi-asserted-by":"crossref","DOI":"10.1177\/2054358120922617","article-title":"Community pharmacy-based eGFR screening for early detection of CKD in high risk patients","volume":"7","author":"Papastergiou","year":"2020","journal-title":"Can J Kidney Health Dis"},{"key":"2026021721502565300_ejhf3683-bib-0124","doi-asserted-by":"crossref","first-page":"964","DOI":"10.2215\/CJN.11961115","article-title":"The See Kidney Disease targeted screening program for CKD","volume":"11","author":"Galbraith","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026021721502565300_ejhf3683-bib-0125","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jchf.2022.06.001","article-title":"It is time to screen for heart failure: Why and how?","volume":"10","author":"Bozkurt","year":"2022","journal-title":"JACC Heart Fail"},{"key":"2026021721502565300_ejhf3683-bib-0126","article-title":"Protocol for a randomized study assessing the feasibility of home-based albuminuria screening among the general population: The THOMAS study","volume":"17","author":"Mil","year":"2022","journal-title":"PLoS One"},{"key":"2026021721502565300_ejhf3683-bib-0127","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/S0140-6736(23)00876-0","article-title":"Participation rate and yield of two home-based screening methods to detect increased albuminuria in the general population in the Netherlands (THOMAS): A prospective, randomised, open-label implementation study","volume":"402","author":"Mil","year":"2023","journal-title":"Lancet"},{"key":"2026021721502565300_ejhf3683-bib-0128","volume-title":"U.S. Department of Health and Human Services","year":"2023"},{"key":"2026021721502565300_ejhf3683-bib-0129","volume-title":"National Diabetes Audit 2021\u201322, Report 1: Care processes and treatment targets, overview","author":"NHS Digital"},{"key":"2026021721502565300_ejhf3683-bib-0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0110535","article-title":"Primary care detection of chronic kidney disease in adults with type-2 diabetes: the ADD-CKD study (awareness, detection and drug therapy in type 2 diabetes and chronic kidney disease)","volume":"9","author":"Szczech","year":"2014","journal-title":"PLoS One"},{"key":"2026021721502565300_ejhf3683-bib-0131","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.2337\/db06-1646","article-title":"Reduction in microalbuminuria as an integrated indicator for renal and cardiovascular risk reduction in patients with type 2 diabetes","volume":"56","author":"Araki","year":"2007","journal-title":"Diabetes"},{"key":"2026021721502565300_ejhf3683-bib-0132","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S2213-8587(18)30314-0","article-title":"Change in albuminuria as a surrogate endpoint for progression of kidney disease: A meta-analysis of treatment effects in randomised clinical trials","volume":"7","author":"Heerspink","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026021721502565300_ejhf3683-bib-0133","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.ajkd.2019.08.007","article-title":"Change in estimated GFR and albuminuria as end points in clinical trials: A viewpoint from the FDA","volume":"75","author":"Thompson","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"2026021721502565300_ejhf3683-bib-0134","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S2213-8587(21)00243-6","article-title":"Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: A prespecified analysis from the DAPA-CKD trial","volume":"9","author":"Jongs","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026021721502565300_ejhf3683-bib-0135","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.7326\/M23-1023","article-title":"Impact of finerenone-induced albuminuria reduction on chronic kidney disease outcomes in type 2 diabetes: A mediation analysis","volume":"176","author":"Agarwal","year":"2023","journal-title":"Ann Intern Med"},{"key":"2026021721502565300_ejhf3683-bib-0136","article-title":"Comparison of urine dipstick and albumin:creatinine ratio for chronic kidney disease screening: A population-based study","volume":"12","author":"Park","year":"2017","journal-title":"PLoS One"},{"key":"2026021721502565300_ejhf3683-bib-0137","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3949\/ccjm.81a.13040","article-title":"Albuminuria: When urine predicts kidney and cardiovascular disease","volume":"81","author":"Stephen","year":"2014","journal-title":"Cleve Clin J Med"},{"key":"2026021721502565300_ejhf3683-bib-0138","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.diabres.2012.12.010","article-title":"Monitoring young people with type 1 diabetes for diabetic nephropathy: Potential errors of annual ACR testing","volume":"99","author":"Oke","year":"2013","journal-title":"Diabetes Res Clin Pract"},{"key":"2026021721502565300_ejhf3683-bib-0139","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1053\/j.ajkd.2012.05.009","article-title":"The diagnostic accuracy of a urine albumin-creatinine ratio point-of-care test for detection of albuminuria in primary care","volume":"60","author":"McTaggart","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"2026021721502565300_ejhf3683-bib-0140","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.2215\/CJN.13341215","article-title":"Effect of processing delay and storage conditions on urine albumin-to-creatinine ratio","volume":"11","author":"Herrington","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026021721502565300_ejhf3683-bib-0141","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1373\/clinchem.2012.195644","article-title":"Albuminuria prevalence in first morning void compared with previous random urine from adults in the National Health and Nutrition Examination Survey, 2009-2010","volume":"59","author":"Saydah","year":"2013","journal-title":"Clin Chem"},{"key":"2026021721502565300_ejhf3683-bib-0142","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.kint.2020.04.020","article-title":"Controversies in acute kidney injury: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference","volume":"98","author":"Ostermann","year":"2020","journal-title":"Kidney Int"},{"key":"2026021721502565300_ejhf3683-bib-0143","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12882-024-03466-5","article-title":"Screening, identifying, and treating chronic kidney disease: Why, who, when, how, and what?","volume":"25","author":"Farrell","year":"2024","journal-title":"BMC Nephrol"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/27\/11\/2357\/66833879\/eurjhf_27_11_2357.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/27\/11\/2357\/66833879\/eurjhf_27_11_2357.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T02:50:55Z","timestamp":1771383055000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/27\/11\/2357\/8470372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,27]]},"references-count":143,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,5,27]]},"published-print":{"date-parts":[[2025,11,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.3683","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,5,27]]},"assertion":[{"value":"2025-01-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}